2012
Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer
Deshpande H, Sheth K, Sosa J, Roman S. Efficacy and Tolerability of Pharmacotherapy Options for the Treatment of Medullary Thyroid Cancer. Clinical Medicine Insights Oncology 2012, 6: cmo.s8305. PMID: 23133319, PMCID: PMC3489097, DOI: 10.4137/cmo.s8305.Peer-Reviewed Original ResearchMedullary thyroid carcinomaProgressive medullary thyroid carcinomaAdvanced medullary thyroid carcinomaManagement of MTCMedullary thyroid cancerAdvanced diseasePharmacotherapy optionsConventional chemotherapyThyroid cancerThyroid carcinomaNovel treatmentsUS FoodDrug AdministrationTreatmentTherapyDiseaseEfficacyTolerabilityChemotherapyPatientsCarcinomaVandetanibCancerAdministration
2011
Medullary thyroid cancer in the past, present and future: from bench to bedside
Deshpande H, Morgensztern D, Sosa J. Medullary thyroid cancer in the past, present and future: from bench to bedside. Expert Review Of Endocrinology & Metabolism 2011, 6: 585-597. DOI: 10.1586/eem.11.44.Peer-Reviewed Original ResearchMedullary thyroid cancerThyroid cancerManagement of MTCMaximum survival benefitSystemic treatment optionsHigh-volume surgeonsMultiple endocrine neoplasiaFirst clinical descriptionRET proto-oncogeneMetastatic diseaseSurvival benefitProphylactic thyroidectomyTreatment optionsSpecialized centersEndocrine neoplasiaClinical descriptionPatientsCancerDiseaseDiagnosisProto-oncogeneImportant advancesThyroidectomyComplicationsSurgery